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Results: A total of 26 lesions were included in the analysis. 
Median follow-up was 14 months (3-41 months). Thirteen 
were metastatic lesions with histology as breast cancer, 
medulloblastoma, adenoid cystic among others. Response 
rates were: 31% complete response and partial response / 
stable at 69%. 13 benign lesions highlighting arteriovenous 
malformations, neurofibroma and melanocytoma. Response 
rates for this group: complete response in 8%, partial 
response / stable at 92%. During the follow-up time only 5 
patients had relapsed 100% to distance. Median overall 
average dose was 21 Gy (14-35 Gy), the median was three 
fractions (1-5 Fractions), median prescription isodose was 
83% (77-88%) with an average coverage of 97.27% (93.13-
100%). There were no data as myelopathy ≥ Grade II 
associated to treatment in the whole cohort, the most 
common symptom after treatment was fatigue. 
 
Conclusion: The treatment of intraspinal tumors with image-
guided robotic SBRT, has proven to be a feasible,safe and 
effective option for treatment, where treatment options are 
scarce. In our experience, the data are encouraging and 
comparable with those reported by other authors. 
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Purpose or Objective: Adult brain stem gliomas are rare 
accounting for 1-2% of adult gliomas. They are heterogeneous 
with varying clinical and radiological presentation. Prognosis 
remains poor because of limited surgical options and 
radiotherapy still remains the main treatment option. We 
report our clinical experience of treating brain stem glioma. 
 
Material and Methods: A Retrospective review was made to 
analyze the clinical presentation, diagnosis, treatment 
outcome and survival in adult brain stem glioma patients 
treated at Shaukat Khanum Memorial Cancer Hospital Lahore. 
Between July 2007 and August 2014. 
 
Results: 46 patients were identified from Hospital record 
system. Diagnosis was mostly based on radiological findings 
with MRI brain and biopsy was done only in 11 patients. 98% 
of the patients were treated with radiotherapy as a first line 
treatment on presentation and 1 patient was kept under 
close surveillance which was treated on progression. Median 
radiotherapy dose used ranged between (20-60Gy) with a 
median dose of 51Gy. Age of the patients ranged from 18 to 
72 years (median 33 years) with a Male to female ratio of 
3:1.Median follow up duration was 9 months (range 1-72). 
Radiological response was seen in 65% (13% partial & 52% 
stable) of the patients. The median overall survival (OS) for 
entire cohort was 10 months. One and two year OS rates 
were 46% and 25% respectively. Radiological Low grade 
Glioma showed a median survival of 11.5 months and was 
found to be 9.5 months for High grade Glioma. (p=0.864). 
ECOG Performance status 0,1,2 and 3 showed median survival 
of 13.6, 11.5, 6 and 3 months respectively (p=.02) 
 
Conclusion: Survival still remains dismal despite high 
radiotherapy dose. The role of cytogenetics and 
chemotherapy should be explored to improve outcome. 
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Purpose or Objective: 
Background: Brain metastases (BM) are the most common 
CNS malignancies. They represent an important cause of 
morbidity and mortality in cancer patients. In the literature, 
few studies have evaluated the efficacy of stereotactic 
reirradiation (SRT) for recurrent brain metastases as a 
salvage treatment option after a prior radiotherapy.  
Objectives: This study reports the clinical outcome and 
tolerance of repeat irradiation with CyberKnife robotic 
stereotactic delivery in patients with recurrent brain 
metastases and a history of prior cerebral radiotherapy. 
Overall survival (OS), intracranial progression-free survival 
(PFS), local control (LC) and prognostic factors associated 
with overall survival (OS) were evaluated. 
 
Material and Methods: Patients treated from April 2010 to 
January 2015 for recurrent brain metastases were 
retrospectively included. Univariate and multivariable 
analyses included age, performance status, recursive 
partitioning analysis (RPA), extratracranial disease control, 
and time from initial RT to SRT. The prior radiotherapy was 
WBRT for 27 patients (dose from 30 Gy to 45 Gy) , 
radiosurgery with Gamma knife for 8 patient (dose from 18 
Gy to 25 Gy) and hypo fractionated stereotactic radiotherapy 
in 2 patients. The tumor size ranged from 1to 4 cm (median 2 
cm).  
 
Results: In total, 37 Patients with 53 recurrent brain 
metastases and a median age of 58 years (Range 33-82 years) 
were included. The median number of metastases per patient 
was 2 (range 1-4), treated with a median dose of 21 Gy 
(range 10-36) per treatment, with a median of 3 fractions 
(range 1-9) per patient. The median follow-up was 10,1 
months (range 1-19 months). The OS rate from the SRT was 
57,2%( IC 95%: 34.6-74.6). Two (5%) of 12 deaths were from 
neurologic causes. The median PFS was 5.8 months (IC 95%: 
3.6-9.3). On multivariate analysis, controlled extracranial 
disease is correlated with better overall survival 31% (IC 95%: 
15-50; p= 0,005). Adverse radiation events developed was 
acceptable.  
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Conclusion: Stereotactic reirradiation with CyberKnife for 
recurrent brain metastases, seems to be a safe and effective 
approach in selected patients. However, in the absence of 
prospective trials, no recommendation can be strongly 
established.  
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Purpose or Objective: Thalamic tumours represent 5.2% of 
all intracranial tumours and are typically diagnosed in the 
paediatric population. These tumors arise from glial cells 
with an aggressive behavior and a high grade histology. They 
have a poor prognosis. The aim of this study was to find new 
approaches for defining the clinical target volume for these 
tumors. 
 
Material and Methods: Clinical data were collected form 
archived files of 30 patients diagnosed with thalamic gliomas 
based on pathologic and radiologic criteria. 
 
Results: Three patterns of tumor spread were found. The 
first pattern followed the thalamic tributaries of the 
posterior part of the internal cerebral veins. These were the 
anterior and superior thalamic veins. For the second pattern 
the close proximity of the internal cerebral vein branches of 
the superior thalamic veins was a potential route of spread 
between the medial surfaces of the thalami. In addition to 
spread across the midline tumours could also spread along 
the adjacent tectal, pineal and/or vermian veins. The third 
pattern of thalamic tumor spread was found in gliomas which 
use the anterior tributaries of the internal cerebral venous 
architecture of the posterior and inferior branches from the 
basal vein of Rosenthal. 
 
Conclusion: Thalamic gliomas spread upon the peritumoral 
architecture of the perivenous/subglial Scherer structures 
and this knowledge should be used for redefining the clinical 
target volume for radiation therapy in thalamic gliomas 
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Purpose or Objective; Evidence for the use of stereotactic 
radiosurgery (SRS) to 1-3 brain metastases (BM) can be 
derived from historic prospective trials. With improvements 
in the ability to control systemic disease, better access to 
SRS and concerns with WBRT associated neurocognitive 
toxicity many institutions now offer SRS to patients with 
greater than 3 metastases. The purpose of this study was to 
review local control and survival outcomes of patients with 4 
or more BM treated with SRS. 
 
Material and Methods: Patients with BM treated with SRS for 
4 or more lesions between June 2011 and April 2015 were 
identified from a prospective database. Patients were 
deemed suitable for SRS if they had preserved Karnofsky 
performance status (> 70), controllable systemic disease and 
an estimated prognosis of > 6 months with a total intracranial 
metastatic volume of < 20 cm3. Local control and overall 
survival rates were estimated using Kaplan Meier curves. 
 
Results: A total of 16 patients (median age 54 years) with 85 
lesions were treated with primary pathology as follows: 
breast 3 (18.6%); lung 5 (31.3%); melanoma 6 (31.3%) and 
others 2 (12.5%). Median number of lesions treated was 5, 
with median total volume of BM per patient of 1.63cm3. 
Minimum follow up post SRS in all patients was 6 months. Six 
(37.5%) patients had received previous WBRT. Eight patients 
(50%) experienced distant intracranial relapse, 6 (75%) of 
whom had not received prior WBRT. Of these 6 patients; 3 
(50%) received salvage WBRT, 2 (33.3%) were suitable for 
further SRS and 1 (16.7%) refused further intervention. Of the 
10 patients who had not received WBRT prior to SRS, 6 had 
confirmed distant relapse. The median whole brain 
radiotherapy free survival (i.e. time from initial SRS to either 
salvage WBRT or death) was 6.1 months. Eleven lesions 
(12.9%) recurred locally after a median of 226 days (range 85 
– 235) post SRS. Median overall survival was 8.3 months 
(range 21 – 548). 
 
Conclusion: The median survival in this series suggests there 
may be a group of patients with greater than 3 metastases 
that could benefit from SRS. Although patient numbers are 
small, this data may suggest that durable whole brain free 
survival (an important quality of life outcome) may be 
achievable in patients initially treated with SRS only. 
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Purpose or Objective: The primary objective of the study is 
to assess the survival and quality of life after re-irradiation of 
relapsing malignant brain tumors. The second objective was 
to evaluate the influence of some prognostic factors on 
survival.  
 
Material and Methods: Fifteen patients received radiation 
re-treatment for relapse in primary brain tumor between 
October 2011 and May 2015. The interval between two 
consecutive treatments was at least 1 year. Treatment was 
carried out with Conformal Radiotherapy (3D-CRT). The total 
dose radiation of the first treatment was 60 Gy, while the 
second treatment was 40-50 Gy. During follow-up, patients 
were evaluated at regular intervals both in taking drugs and 
corticosteroids for the performance status. Radiological 
response was evaluated by examining all available imaging 
